Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a foreign private issuer, reported to the U.S. Securities and Exchange Commission (SEC) that on August 6, 2024, it entered into a securities purchase agreement with certain investors, including senior management and existing shareholders. The private placement offering was conducted at a 10% premium to the closing price on the Nasdaq Capital Market on the agreement date. The company agreed to sell 800,000 ordinary shares and warrants to purchase an additional 800,000 shares at $0.75 each. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. The warrants are immediately exercisable upon issuance with a 5-year term and an exercise price of $0.75 per share. They may be exercised on a cashless basis if no effective...Show More